---
layout: post
title: "QTc Information in Human Prescription Drug and Biological Product Labeling; Guidance for Industry; Availability"
date: 2026-02-04 21:36:59 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-21798
original_published: 2025-12-03 00:00:00 +0000
significance: 8.00
---

# QTc Information in Human Prescription Drug and Biological Product Labeling; Guidance for Industry; Availability

**Published:** February 04, 2026 21:36 UTC
**Source:** Federal Register
**Original Published:** December 03, 2025 00:00 UTC
**Document Number:** 2025-21798

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled "QTc Information in Human Prescription Drug and Biological Product Labeling." This guidance is intended to assist applicants with incorporating heart rate-corrected QT (QTc) interval prolongation-related information into the labeling of non-antiarrhythmic human prescription drug and biological products. The guidance provides recommendations on how and where to appropriately include the clinically relevant information on QTc interval prolongation in the labeling, in accordance with regulatory requirements for the content and format of human prescription drug labeling. This guidance finalizes the draft guidance of the same title issued on August 8, 2023.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/03/2025-21798/qtc-information-in-human-prescription-drug-and-biological-product-labeling-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2025-21798

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
